Benloucif S, Galloway M P
Department of Psychiatry, Wayne State University School of Medicine, Lafayette Clinic, Detroit, MI 48207.
Eur J Pharmacol. 1991 Jul 23;200(1):1-8. doi: 10.1016/0014-2999(91)90658-d.
Using microdialysis, changes in extraneuronal levels of dopamine (DA), and the metabolites of DA and serotonin (5-HT), were monitored concurrent with perfusion of 5-HT1 agonists into the anterior striata of anesthetized rats. Perfusion of 5-HT facilitated DA release in a dose dependent manner, and to a greater extent than any other agonist tested. Extraneuronal DA levels increased 34% with perfusion of 0.04 nmol 5-HT and 18-fold with perfusion of 4.0 nmol 5-HT. Perfusion with multiple doses of either 1-(m-chlorophenyl)piperazine (m-CPP) or trifluoromethylphenylpiperazine (TFMPP) also resulted in a dose-dependent facilitation of DA release with a 40% increase in extracellular DA produced by either 0.4 nmol m-CPP or 10.0 nmol TFMPP. A 50-fold increase in DA followed 40.0 nmol m-CPP, while 160 nmol TFMPP enhanced DA 11-fold. Local application of either 5-methoxy-3(1,2,3,6-tetrahydro-4-pyridinyl)-1H indole succinate (RU24969) or 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT) (2.0 nmol perfused over 20 min) increased extracellular DA by 300 and 40%, respectively. RU24969 (2.0 nmol) also facilitated DA release following systemic pretreatment with 8-OH-DPAT (100 micrograms/kg). Perfusion with fenfluramine to release endogenous 5-HT also increased extraneuronal DA in a dose-dependent manner, and this facilitation was prevented by pretreatment with the 5-HT reuptake inhibitor fluoxetine. The facilitation of DA release by 0.4 nmol 5-HT was reduced by pretreatment with the 5-HT1 antagonist pindolol (4.0 nmol). These results suggest that serotonergic innervation of the anterior striatum may exert a facilitatory influence on DA release.
利用微透析技术,在向麻醉大鼠的前纹状体灌注5-羟色胺(5-HT)1激动剂的同时,监测细胞外多巴胺(DA)水平以及DA和5-羟色胺(5-HT)代谢产物的变化。灌注5-HT以剂量依赖方式促进DA释放,且程度大于所测试的任何其他激动剂。灌注0.04 nmol 5-HT时,细胞外DA水平增加34%,灌注4.0 nmol 5-HT时增加18倍。多次灌注1-(间氯苯基)哌嗪(m-CPP)或三氟甲基苯基哌嗪(TFMPP)也导致DA释放呈剂量依赖性促进,0.4 nmol m-CPP或10.0 nmol TFMPP使细胞外DA增加40%。40.0 nmol m-CPP后DA增加50倍,而160 nmol TFMPP使DA增加11倍。局部应用5-甲氧基-3(1,2,3,6-四氢-4-吡啶基)-1H吲哚琥珀酸盐(RU24969)或8-羟基-2-(二正丙基氨基)四氢萘氢溴酸盐(8-OH-DPAT)(2.0 nmol在20分钟内灌注)分别使细胞外DA增加300%和40%。RU24969(2.0 nmol)在经8-OH-DPAT(100微克/千克)全身预处理后也促进DA释放。灌注芬氟拉明以释放内源性5-HT也以剂量依赖方式增加细胞外DA,且这种促进作用可被5-HT再摄取抑制剂氟西汀预处理所阻断。0.4 nmol 5-HT对DA释放的促进作用可被5-HT1拮抗剂吲哚洛尔(4.0 nmol)预处理所减弱。这些结果表明,前纹状体的5-羟色胺能神经支配可能对DA释放发挥促进作用。